Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 937-942, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-90544
ABSTRACT
We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Presión Sanguínea
/
Proteínas Tirosina Quinasas
/
Ecocardiografía Doppler
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Estudios de Seguimiento
/
Disnea
/
Corazón
/
Hipertensión
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS